Intravenous flecainide exerted negative inotropic effects, decreasing ejection fraction by 9% in patients without heart failure, 13% in those on beta-blockers, and 20% in overt heart failure.
Observational (n=20)
Does intravenous flecainide exert differential haemodynamic effects in patients with coronary disease with and without heart failure or beta-blocker therapy?
Intravenous flecainide exerts significant negative inotropic effects, particularly increasing systemic vascular resistance in patients with overt heart failure, highlighting the need for caution in patients with left ventricular dysfunction.
The haemodynamic effects of flecainide were compared in three different subsets of patients with documented coronary disease. Ten patients (A) had no heart failure, 5 patients were on beta blockers (B) and 5 patients had overt heart failure (C). Flecainide was associated with negative inotropic effects that were relatively more pronounced in patients with left ventricular dysfunction: pulmonary wedge pressure increased by 27% in A, by 31% in B and by 42% in C; left ventricular stroke volume and stroke work decreased respectively by 10 and 12% in A, 21 and 19% in B, 26 and 28% in C. Ejection fraction decreased by 9% in A, 13% in B and 20% in C, in relation with an increase in end systolic volume (+9% in A, +10% in B and +5% in C). Absolute changes, however, were not significantly different from one group to another except for the increase of systemic vascular resistance which was more pronounced in C as compared with the other groups. The myocardial depression was also confirmed by the fall in dP/dt that was maximal at the end of injection; dP/dt remained depressed 15 min later despite some improvement. Flecainide thus exerts negative inotropic effects that are maximal at the end of infusion and may be of importance in patients with established left ventricular dysfunction.
LEGRAND et al. (Thu,) conducted a observational in Documented coronary disease (n=20). Intravenous flecainide vs. Comparison across subgroups (no heart failure, on beta-blockers, overt heart failure) was evaluated on Haemodynamic effects (including pulmonary wedge pressure, stroke volume, stroke work, and ejection fraction). Intravenous flecainide exerted negative inotropic effects, decreasing ejection fraction by 9% in patients without heart failure, 13% in those on beta-blockers, and 20% in overt heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: